Mainz Biomed (NASDAQ:MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets.
Source: Seeking Alpha
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
